Autologous stem cell transplantation in T-cell/histiocyte-rich large B-cell lymphoma: EBMT Lymphoma Working Party study
Year: 2024
Type: article
Study design: Observational Study
Abstract: ABSTRACT: Although broadly used, consolidative autologous hematopoietic stem cell transplantation (auto-HCT) for relapsed/refractory (R/R) T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) has never been specifically investigated. Here, we have analyzed outcomes of auto-HCT for THRLBCL compared with diffuse large cell B-cell lymphoma not otherwise specified (DLBCL). Eligible for this retrospective registry study were adult patients with R/R THRLBCL and DLBCL, respectively, who underwent a first auto-HCT in a salvage-sensitive disease status as assessed by positron emission tomography-computed tomography between 2016 and 2021 and were registered with the European Society for Blood and Marrow Transplantation database. The primary end point was progression-free survival (PFS) 2 years after transplantation. A total of 201 patients with THRLBCL and 5543 with DLBCL were included. There were no significant differences in terms of disease status at HCT, pretreatment lines, and interval from diagnosis to transplant between the cohorts, but patients with THRLBCL were significantly younger, contained a higher proportion of men, and had a better performance status. Compared with DLBCL, THRLBCL was associated with significantly better 2-year PFS (78% vs 59%; P < .001) and overall survival (OS, 81% vs 74%; P = .02) because of a significantly lower 2-year relapse incidence (16% vs 35%; P < .001). On multivariate analysis, favorable relapse risk (hazard ratio [HR], 0.46; 95% confidence interval [CI], 0.31-0.7) and PFS (HR, 0.58; 95% CI, 0.41-0.82) of patients with THRLBCL remained significant, whereas OS benefits (HR, 0.78; 95% CI, 0.54-1.12) did not. These results were validated in a propensity score-matched analysis. These data prove auto-HCT as an effective treatment option for salvage-sensitive R/R THRLBCL.
Source: Blood Advances
Authors: Simon Renders, Maud Ngoya, Herve Finel, Marie-Thérèse Rubio, William Townsend, Roland Schroers, Urban Novak, Nicolaas Schaap, Mahmoud Aljurf, Grzegorz Helbig, Matthew Collin, Guido Kobbe, Anne Huynh, José Antonio Pérez-Simón, Adrian Bloor, Hervé Ghesquieres, Anna Sureda, Norbert Schmitz, Bertram Glass, Peter Dreger
Institutions: Heidelberg University, University Hospital Heidelberg, European Society for Blood and Marrow Transplantation, Centre Hospitalier Régional et Universitaire de Nancy, University College Hospital, University College London, Universitätsklinikum Knappschaftskrankenhaus Bochum, Ruhr University Bochum, University of Bern, University Hospital of Bern, Radboud University Nijmegen, Radboud University Medical Center, King Faisal Specialist Hospital & Research Centre, Medical University of Silesia, Freeman Hospital, Newcastle University, Heinrich Heine University Düsseldorf, Centre Hospitalier Universitaire de Toulouse, Institut universitaire du cancer de Toulouse Oncopole, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Universidad de Sevilla, The Christie Hospital, The Christie NHS Foundation Trust, Lyon 1 Université, Hospices Civils de Lyon, Hôpital Lyon Sud, Institut Català d'Oncologia, University of Münster, University Hospital Münster, Helios Hospital Berlin-Buch
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,000
OpenAlex ID: W4402037316